Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698
Autoimmune Diseases, Blood Coagulation Disorders
Rochester, Minnesota, United States
View Trial DetailsNCT Number: NCT06919341
Primary immune thrombocytopenia (PIT), previously referred to as idiopathic thrombocytopenic purpura, is an acquired disease characterized by accelerated platelet destruction and deficient platelet production by megakaryocytes.
Although the existence of PIT has been known for decades, there is no consensus on its triggering mechanisms. On the other hand, this disease presents a very heterogeneous patient profile, both in its characteristics and treatments. In this sense, the diagnosis is still made by excluding other causes of thrombocytopenia.
There is insufficient epidemiological data on the disease, a fact that is especially evident in our country. We have no data on the incidence or prevalence of this pathology in Spain.
For all these reasons, this epidemiological study has been designed to increase the available knowledge about this disease and the detailed characterization of the population of patients with ITP in Spain.
The main objective of this study is to describe the clinical, analytical and treatment characteristics of primary immune thrombocytopenia and other immune thrombocytopenia.
The study is an epidemiological, ambispective, multicenter study carried out in hospitals in Spain.
Information will be collected on the disease under study, as well as on the treatments received, using the patient's clinical history as a source document.
Interested in participating?
Request Info2 month and older
All sexes
Observational
Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment
Time frame: From enrollment
Time frame: From enrollment
Time frame: From enrollment
Time frame: From enrollment
Contact information is provided by the study sponsor or research team.
Amanda López Picado
CONTACT
Cristina Pascual Izquierdo, MD
CONTACT
Fundación Española de Hematología y Hemoterapía
Other
Acronym: RESTI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07549698
Autoimmune Diseases, Blood Coagulation Disorders
Rochester, Minnesota, United States
View Trial DetailsNCT07083960
AIHA - Cold Autoimmune Hemolytic Anemia, AIHA - Warm Autoimmune Hemolytic Anemia
Canberra, Australian Capital Territory, Australia
View Trial DetailsNCT07194850
Autoimmune Diseases, Blood Coagulation Disorders
Bordeaux, France
View Trial DetailsNCT07133659
Autoimmune Diseases, Blood Coagulation Disorders
Baghdad, Iraq
View Trial Details